长期致力于精神疾病的发生机制及诊疗靶标的研究，主持多项国家级和专项基金科研课题，其中7项中国及加拿大重大新药创制项目，发现“受体-受体复合物”新信号通路，提出以病理状态下特异性参与疾病发生的受体复合物为精神疾病治疗靶点的新策略。在Nature, Cell, Nature Medicine, Neuron, JCI 等杂志发表150余篇学术论文，Science 及Trends Neurosci 专题评述其系列成果开辟了受体调节的崭新领域，他引6000余次。获授权国际专利19项。获加拿大精神疾病研究基金会奖 (CPRF)、美国大脑与行为研究基金会奖(NASARD) 和美国神经精神药理学学院奖 (ACNP) 等。
Dr. Liu Fang has been deeply committed to the study of the pathogenesis and therapeutic targets of mental disorders. She has led numerous national and special fund research projects, including seven major new drug development initiatives in both China and Canada. Her groundbreaking discovery of the "receptor-receptor complex" signaling pathway has introduced a novel therapeutic strategy that targets receptor complexes specifically involved in disease progression under pathological conditions for the treatment of mental illnesses. With over 150 academic papers published in prestigious journals such as Nature, Cell, Nature Medicine, Neuron, and JCI, her series of achievements have been highlighted in special reviews in Science and Trends in Neuroscience, marking a new frontier in receptor regulation, and have been cited over 6,000 times. She holds 19 authorized international patents and has been honored with prestigious awards including the Canadian Psychiatric Research Foundation Award (CPRF), the National Alliance for Research on Schizophrenia and Depression Award (NASARD), and the American College of Neuropsychopharmacology Award (ACNP).
